Immuron Ltd — Regulatory Filings 2007

Dec 13, 2007

==> picture [68 x 76] intentionally omitted <==

Company Announcement

Anadis Limited Appoints The Bank of New York Mellon as Depositary for its U.S. ADR Program

Friday 14 December 2007

NEW YORK, December 14, 2007 – Anadis Limited, an Australian biotechnology company (ASX:ANX), has selected The Bank of New York Mellon as the depositary bank for its American depositary receipt (ADR) program. Each Anadis Limited ADR represents twenty ordinary shares. The ADRs trade on the Over-the-Counter market under the symbol “ANDIY”

Anadis Limited (www.anadis.com) is a world’s leader in polyclonal antibody-based health products. Anadis’ proprietary, rapid manufacturing technology has enabled it to develop a product pipeline of polyclonal antibody-based solutions to a range of important infectious and immune-mediated diseases. Products in the market and under development include a portfolio of Anti-LPS products (to fight against E.coli , Irritable Bowel Syndrome –IBS, Oral/ Gastrointestinal Mucositis and Inflammatory Bowel Disease- IBD) and other specific antibody-based solutions including a novel product containing anti-flu antibodies.

The all-natural dairy-derived platform, and its regulatory classification as GRAS (Generally Regarded as Safe) when administered orally allows for a significantly shorter time-frame from bench to market compared with typical biotechnology products. The platform also possesses dramatically lower manufacturing costs and higher scalability compared to typical antibody-based solutions.

“The ADR program is an another milestone in our plan to become a global leader in the biotechnology space” stated Dr. Zeil Rosenberg, the company’s CEO. “ The ADR program will enable us to further broaden our investor base in the U.S., enabling easier trading in our shares. It was only natural for us to choose the Bank of New York, the global leader in ADR programs to be our depositary receipts institution.”

The Bank of New York Mellon's Depositary Receipt business is conducted through The Bank of New York subsidiary, which acts as depositary for more than 1,290 American and global depositary receipt programs, acting in partnership with leading companies from 61 countries. With an unrivalled commitment to helping securities issuers succeed in the world's rapidly evolving financial markets, the Company delivers the industry's most comprehensive suite of integrated depositary receipt, corporate trust and stock transfer services. Additional information is available at www.adrbny.com.

==> picture [49 x 55] intentionally omitted <==

For further information contact:

Dr. Zeil Rosenberg - CEO

Email: zeil.r@anadis.com.au Tel: +1 201 750 4799

Arie Nudel – Investor Relations Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

About Anadis Limited

Anadis Limited (ASX: ANX) is a research-driven bio-pharmaceutical company focused on antibody-based health products. Anadis’ proprietary, rapid manufacturing technology has enabled it to develop a product pipeline of polyclonal antibody-based solutions to a range of important infectious and immune-mediated diseases. The allnatural, dairy-derived, orally administered platform, and its regulatory classification as GRAS (Generally Regarded as Safe), allows for a significantly shorter time-frame from bench to market compared with typical biotechnology products. The platform also possesses dramatically lower manufacturing costs and higher scalability compared to typical antibody-based solutions. Anadis is addressing existing market opportunities sized in excess of US$30 billion. Leveraging a technology platform that has been carefully developed over a decade, the company expects to become the leading provider of proprietary polyclonal antibody-based solutions worldwide.

For further information please visit www.anadis.com.

This release is for informational purposes only. Anadis Limited provides no advice nor recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. Depositary Receipts: Not FDIC, State or Federal Agency Insured; May Lose Value; No Bank, State or Federal Agency Guarantee.

==> picture [49 x 55] intentionally omitted <==